Replies to post #10124 on Aurinia Pharmaceuticals Inc (AUPH)

[somerssalt]

Worth reposting:

“The Efficacy and Safety of Belimumab in Patients with Active Lupus Nephritis (BLISS-LN) study, involving 448 patients, met its primary endpoint demonstrating that a statistically significant greater number of patients achieved Primary Efficacy Renal Response (PERR) over two years when treated with belimumab plus standard therapy compared to placebo plus standard therapy in adults with active LN (43% vs 32%, odds ratio (95% CI) 1.55 (1.04, 2.32), p=0.0311).”

Oh yeah Benlysta is considerably crappier. 11% delta vs 18% for VOC and a p value of .0311 for VOC <.001. Yeah not worried at all